Forum: Pharming » Pharming Juli-2021

Met IEX wordt u een betere belegger en verhoogt u het rendement op uw beleggingen

Vanaf 10,47 per maand leest u dagelijks onze professionele aandelenanalyses en kooptips.

Krijg toegang tot vele voordelen

Onbeperkt toegang tot onze Premium-content
Ons magazine IEX Expert (digitaal of papier)
Toegang tot onze 3 modelportefeuilles

Profiteer van de IEX producten

3 Modelportefeuilles
Dividendkalender
Aandelenselector

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Laatste koers (eur) 0,996 24 mrt 2023 17:37

Verschil +0,006 (+0,61%) Dagrange 0,981 - 1,020

Volume 7.574.128 Gem. (3M) 8,1M

LL 30 juli 2021 16:03

Takeda Q1 (April 2021-March 2022) HAE highlights

Revenue
Revenue in Hereditary Angioedema (“HAE”) was 39.0 billion JPY, a year-on-year increase of 0.7 billion JPY, or 1.8%.
Sales of TAKHZYRO were 25.5 billion JPY, an increase of 2.2 billion JPY, or 9.6%, versus the same period of the
previous fiscal year primarily due to new launches including prefilled syringe administration in Europe. Sales of FIRAZYR
decreased by 1.2 billion JPY, or 15.1%, to 6.9 billion JPY, primarily due to the continued impact of generic entrants in the
U.S.

Rare Genetics & Hematology
In Rare Genetics & Hematology, Takeda focuses on hereditary angioedema to transform the treatment paradigm, including
through TAKHZYRO, and on rare hematology and rare metabolic diseases, with the aim to deliver functional cures in a
select group of diseases using novel modalities and platforms.

TAKHZYRO / Generic name: lanadelumab
– In July 2021, Takeda announced the results from two final analyses from the Phase 3 HELP (Hereditary
Angioedema Long-term Prophylaxis) Study™ Open-label Extension (OLE), which evaluated the long-term safety
(primary endpoint) and efficacy of TAKHZYRO (lanadelumab) 300 mg every two weeks for up to 2.5 years. In the
first analysis, the mean (min, max) reduction in the attack rate compared to baseline observed in the study
population (N=212) was of 87.4 percent (-100; 852.8), and the median reduction was 97.7 percent and patients
received treatment for a mean (standard deviation) duration of 29.6 (8.2) months. At steady state – day 70 to the end
of the treatment period – attack rates were further reduced to a mean of 92.4 percent and a median reduction of 98.2
percent. An additional analysis further suggests TAKHZYRO was a well-tolerated treatment that prevented HAE
attacks over an extended planned 132 week treatment period across specific HAE patient demographic and disease
characteristic subgroups. These data were presented at the 2021 European Academy of Allergy and Clinical
Immunology (EAACI) Hybrid Congress.

Bijlage:

Direct naar Forum

Pharming Group Meer »

Koers	0,996	Verschil	+0,01 (+0,61%)
Laag	0,981	Volume	7.574.128
Hoog	1,020	Gem. Volume	8.065.068
24 mrt 2023 17:37

Koers

0,996

Verschil

+0,01 (+0,61%)

Laag

0,981

Volume

7.574.128

Hoog

1,020

Gem. Volume

8.065.068

24 mrt 2023 17:37

Pharming Nieuws

Gerelateerde Video's

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Beurscodes, betekenis en hulp bij zoeken

Europa

Noord-Amerika

Kunt u een instrument niet vinden?

Waar vind ik die ISIN code?

Inloggen

Met IEX wordt u een betere belegger en verhoogt u het rendement op uw beleggingen

Krijg toegang tot vele voordelen

Profiteer van de IEX producten

Nederland

Europa

Amerika

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Melding

Pharming Juli-2021

HobbyBeurs

Aanbevelingen

Aantal posts: 1.590

LL

Aanbevelingen

Aantal posts: 5.649

Meedoen aan de discussie?

Direct naar Forum

Pharming Group Meer »

Belangrijke update Pharming rond toelating leniolisib

Pharming Nieuws

Gerelateerde Video's

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

SynVest

DEGIRO

Trade Republic

ER Capital

Raisin

Meld u aan voor de IEX dagelijkse nieuwsbrief

Verzoek